1. Home
  2. VIVS vs REVB Comparison

VIVS vs REVB Comparison

Compare VIVS & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

N/A

Current Price

$0.28

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

N/A

Current Price

$3.69

Market Cap

1.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VIVS
REVB
Founded
2007
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
1.9M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
VIVS
REVB
Price
$0.28
$3.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $76.25
AVG Volume (30 Days)
★ 898.1K
11.8K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 72.68
EPS
★ N/A
N/A
Revenue
★ $4,603,000.00
N/A
Revenue This Year
$228,144.28
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 8.82
N/A
52 Week Low
$0.12
$0.44
52 Week High
$3.40
$4.75

Technical Indicators

Market Signals
Indicator
VIVS
REVB
Relative Strength Index (RSI) 75.73 55.78
Support Level $0.27 $0.93
Resistance Level $0.30 $4.06
Average True Range (ATR) 0.03 0.40
MACD 0.01 -0.14
Stochastic Oscillator 88.82 19.70

Price Performance

Historical Comparison
VIVS
REVB

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: